Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for t(8;21) AML
NCT04257175Phase 3Unknown
- Sponsor
- Sheba Medical Center
- Start
- Feb 2020
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of anti-CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by Sheba Medical Center. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04257175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04257175.